Quick Answer
C4 Therapeutics, Inc. reported Cash and Equivalents of $74.60 million for fiscal year 2025.
C4 Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $74.60M | +34.4% |
| 2024 | $55.50M | -56.2% |
| 2023 | $126.59M | +325.5% |
| 2022 | $29.75M | -60.9% |
| 2021 | $76.12M | -58.1% |
| 2020 | $181.73M | +100.7% |
| 2019 | $90.55M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $58.81M | -1.4% | -24.8% |
| June 30, 2025 | $78.16M | +6.9% | +52.4% |
| March 31, 2025 | $51.29M | -42.8% | -7.6% |
| December 31, 2024 | $55.50M | -56.2% | -7.0% |
| September 30, 2024 | $59.65M | -2.2% | -18.4% |
| June 30, 2024 | $73.11M | +62.9% | -18.5% |
| March 31, 2024 | $89.66M | +81.2% | -29.2% |
| December 31, 2023 | $126.59M | +325.5% | +107.6% |
- C4 Therapeutics, Inc. showed an increase of +34.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, C4 Therapeutics, Inc.’s cash and equivalents has declined by 17.6% (from $90.55 million to $74.60 million).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: